The "dual-home-market" strategy has enabled Chinese Al pharmaceutical companies to enter the global first tier in 10 years' time
A deep dive into one AI pharma breakthrough with our video featuring Insilico Medicine that came up with the world's first AI-discovered drug to complete Phase II trials as a "clinical proof-of-concept milestone", hailed by Nature Medicine this June.
Their secret? A "Dual-Home Strategy":
Team: A pioneering dual-CEO model (AI + pharma leadership) that bridges the gap between algorithms and clinical development.
Financing: Balanced investment from China and overseas markets builds both resilience and global reach.
Clinical: R&D built on local data + international trials
The road ahead means raising success rates, accelerating Phase III, and proving revenue sustainability.
Companies like Insilico Medicine are heralding a new dimension in life sciences where algorithms gain warmth, decisions are data-driven, and every step of drug discovery is optimized by AI. This is transforming healthcare accessibility with precision treatment becoming possible for every patient.